HOWL

SEC source: 0001231919-25-000406 · form4-11042025_121111.xml · nonDerivative · entry 2

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,241,673

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F6 · shares: The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology.

F7 · price: . The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology.

SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,355,717

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology.

SEC source: 0001134657-25-000004 · form4-11042025_121110.xml · nonDerivative · entry 1

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 4,076,920

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014 and 604,989 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-25-000406 · form4-11042025_121111.xml · nonDerivative · entry 1

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,355,717

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology.

SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 3

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,442,653

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F9 · shares: The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11 · ownership.nature: The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology.

SEC source: 0001231919-25-000375 · form4-10292025_111033.xml · nonDerivative · entry 3

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 4,132,715

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F8 · shares: The were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014 and 12,823 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014 and 613,293 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-25-000374 · form4-10292025_111051.xml · nonDerivative · entry 3

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,442,653

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F9 · shares: The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11 · ownership.nature: The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology.

SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 2

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,576,893

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F6 · shares: The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology.

SEC source: 0001231919-25-000375 · form4-10292025_111033.xml · nonDerivative · entry 2

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 4,218,869

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F5 · shares: The were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014 and 6,598 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014 and 626,116 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-25-000374 · form4-10292025_111051.xml · nonDerivative · entry 2

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,576,893

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F6 · shares: The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology.

SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,645,961

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 26,045 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology.

SEC source: 0001231919-25-000375 · form4-10292025_111033.xml · nonDerivative · entry 1

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 4,263,196

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,085 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014 and 632,714 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-25-000374 · form4-10292025_111051.xml · nonDerivative · entry 1

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 6,645,961

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2 · shares: The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 26,045 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology.

SEC source: 0000950170-25-086171 · ownership.xml · derivative · entry 1

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086174 · ownership.xml · derivative · entry 1

Lazarus Alon · CIK 0001808244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086169 · ownership.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086173 · ownership.xml · derivative · entry 1

Morrison Briggs · CIK 0001654430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086172 · ownership.xml · derivative · entry 1

Chatterjee Meeta · CIK 0001835388 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086168 · ownership.xml · derivative · entry 2

Singhal Anil K. · CIK 0001982984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,358

Underlying: Common Stock · 8,358 shares

Expires 2035-06-11

F3 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086167 · ownership.xml · derivative · entry 1

Atkins Michael B. · CIK 0002004793 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-25-086168 · ownership.xml · derivative · entry 1

Singhal Anil K. · CIK 0001982984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2035-06-10

F1 · shares: Represents stock options that the Reporting Person was entitled to receive pursuant to the non-employee director compensation policy of Werewolf Therapeutics, Inc. (the "Company") in effect at the time of the Reporting Person's appointment to the board of directors of the Company, which were not previously granted due to a clerical error.

F2 · derivative.exercise_date: The option was granted on June 11, 2025. One-third of the total number of shares underlying the option vest on February 19, 2026, and the remaining shares vest thereafter in equal monthly installments until February 19, 2028, subject to continued service by the Reporting Person as a director to the Company through each applicable vesting date.

SEC source: 0001415889-25-012942 · form4-05142025_100514.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,237,482

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.96 to $0.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.

SEC source: 0001415889-25-012942 · form4-05142025_100514.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,074,943

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.96 to $0.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.

SEC source: 0001415889-25-012942 · form4-05142025_100514.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,021,969

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82 to $0.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.

SEC source: 0000950170-25-062970 · ownership.xml · derivative · entry 1

Bloom Steven H. · CIK 0001722642 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,720

Underlying: Common Stock · 201,720 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option was granted as an inducement material to Mr. Bloom's entering into employment with Werewolf Therapeutics, Inc. (the "Company") in accordance with Nasdaq Listing Rule 5635(c)(4). The option has a ten-year term and vests as to 25% on April 16, 2026, the first anniversary of the effective date of Mr. Bloom's employment, and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to the Company or any of its subsidiaries through each applicable vesting date.

SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 4

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 42,842 shares

Expires 2025-08-13

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.

F5 · derivative.exercise_date: Immediately exercisable.

F7 · ownership.nature: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology.

SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 3

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 8,031 shares

Expires 2025-04-09

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.

F5 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.nature: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology.

SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · nonDerivative · entry 2

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 6,718,670

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.

F4 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · nonDerivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM BioImpact LLC · CIK 0001687078 · 10% owner

MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner

MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 6,723,056

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.

F2 · ownership.nature: The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

SEC source: 0001415889-25-011570 · form4-04302025_080434.xml · derivative · entry 4

EVNIN LUKE · CIK 0001134657 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 24,098 shares

Expires 2025-08-13

F1 · kind: On March 27, 2025, the Reporting Person exercised warrants to purchase an aggregate of 28,113 shares of the Company's Common Stock for $0.09 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 2,425 of the warrant shares to pay the exercise price and issuing the remaining 25,688 shares.

F4 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.nature: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014 and 5,355 by MPM OIF.

SEC source: 0001415889-25-011570 · form4-04302025_080434.xml · derivative · entry 3

EVNIN LUKE · CIK 0001134657 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,015 shares

Expires 2025-04-09

F1 · kind: On March 27, 2025, the Reporting Person exercised warrants to purchase an aggregate of 28,113 shares of the Company's Common Stock for $0.09 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 2,425 of the warrant shares to pay the exercise price and issuing the remaining 25,688 shares.

F4 · derivative.exercise_date: Immediately exercisable.

F5 · ownership.nature: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.

SEC source: 0001415889-25-011570 · form4-04302025_080434.xml · nonDerivative · entry 2

EVNIN LUKE · CIK 0001134657 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,309,860

F1 · kind: On March 27, 2025, the Reporting Person exercised warrants to purchase an aggregate of 28,113 shares of the Company's Common Stock for $0.09 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 2,425 of the warrant shares to pay the exercise price and issuing the remaining 25,688 shares.

F3 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014 and 639,659 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein

SEC source: 0001415889-25-011570 · form4-04302025_080434.xml · nonDerivative · entry 1

EVNIN LUKE · CIK 0001134657 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,312,285

F1 · kind: On March 27, 2025, the Reporting Person exercised warrants to purchase an aggregate of 28,113 shares of the Company's Common Stock for $0.09 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 2,425 of the warrant shares to pay the exercise price and issuing the remaining 25,688 shares.

F2 · ownership.nature: The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-011574 · form4-04302025_080449.xml · derivative · entry 4

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Foley Todd · CIK 0001473930 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 18,743 shares

Expires 2025-08-13

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.

F4 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.nature: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B) and 585 by AM BV 2014.

SEC source: 0001415889-25-011574 · form4-04302025_080449.xml · derivative · entry 3

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Foley Todd · CIK 0001473930 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,015 shares

Expires 2025-04-09

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.

F4 · derivative.exercise_date: Immediately exercisable.

F5 · ownership.nature: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.

SEC source: 0001415889-25-011574 · form4-04302025_080449.xml · nonDerivative · entry 2

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Foley Todd · CIK 0001473930 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,208,793

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.

F3 · ownership.nature: The shares are held as follows: 2,914,123 by BV 2014, 194,367 by MPM 2014(B) and 100,303 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

SEC source: 0001415889-25-011574 · form4-04302025_080449.xml · nonDerivative · entry 1

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

Foley Todd · CIK 0001473930 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,210,756

F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.

F2 · ownership.nature: The shares are held as follows: 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014.Todd Foley is a Managing Director of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

SEC source: 0000950170-25-025022 · ownership.xml · derivative · entry 1

Singhal Anil K. · CIK 0001982984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-02-18

F1 · derivative.exercise_date: The option was granted on February 19, 2025. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.

SEC source: 0000950170-25-002336 · ownership.xml · derivative · entry 2

HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,652

Underlying: Common Stock · 185,652 shares

Expires 2034-12-31

SEC source: 0000950170-25-002336 · ownership.xml · derivative · entry 1

HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 592,690

Underlying: Common Stock · 592,690 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

SEC source: 0000950170-25-002344 · ownership.xml · derivative · entry 2

Trost Timothy W. · CIK 0001571865 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,358

Underlying: Common Stock · 60,358 shares

Expires 2034-12-31

SEC source: 0000950170-25-002344 · ownership.xml · derivative · entry 1

Trost Timothy W. · CIK 0001571865 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

SEC source: 0000950170-25-002362 · ownership.xml · derivative · entry 1

Lubman Ellen · CIK 0001857842 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,900

Underlying: Common Stock · 131,900 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

SEC source: 0000950170-25-002343 · ownership.xml · derivative · entry 2

Isaacs Randi · CIK 0001857797 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,151

Underlying: Common Stock · 68,151 shares

Expires 2034-12-31

SEC source: 0000950170-25-002343 · ownership.xml · derivative · entry 1

Isaacs Randi · CIK 0001857797 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

SEC source: 0000950170-25-002342 · ownership.xml · derivative · entry 2

Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,129

Underlying: Common Stock · 153,129 shares

Expires 2034-12-31

SEC source: 0000950170-25-002342 · ownership.xml · derivative · entry 1

Karunatilake Chulani · CIK 0001867326 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

SEC source: 0000950170-24-064833 · ownership.xml · derivative · entry 1

EVNIN LUKE · CIK 0001134657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2034-05-23

F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0000950170-24-064829 · ownership.xml · derivative · entry 1

Lazarus Alon · CIK 0001808244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2034-05-23

F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

SEC source: 0001415889-24-014591 · form4-05242024_110533.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2034-05-23

F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to Derek DiRocco's continued service as a director.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Derek.DiRocco is a Partner of the Adviser, who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.